These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 26598783

  • 1. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC.
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
    Shah S, Nikam B, Kale M, Jamale V, Chavan D.
    Dermatol Ther; 2021 Jan; 34(1):e14650. PubMed ID: 33296549
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
    Singh SK, Singnarpi SR.
    Indian J Dermatol Venereol Leprol; 2021 Jan; 87(2):214-222. PubMed ID: 33769732
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S.
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [Abstract] [Full Text] [Related]

  • 6. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J, Simková M, Vanecková J, Hroch M, Chládkova J, Martínková J, Vávrová J, Beránek M.
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [Abstract] [Full Text] [Related]

  • 7. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
    Tournier A, Khemis A, Maccari F, Reguiai Z, Bégon E, Fougerousse AC, Amy de la Breteque M, Beneton N, Parier J, Boyé T, Avenel-Audran M, Girard C, Pallure V, Perrot JL, Bastien M, Mahé E, Beauchet A, GEM Resopso.
    Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA, Galluccio A, Pezza M, Vestita M, Cassano N.
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [Abstract] [Full Text] [Related]

  • 9. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 10. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [Abstract] [Full Text] [Related]

  • 11. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F, Ruffo G, Ricceri F, Pescitelli L, Lotti T.
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S, Krishna V, Kanwar AJ.
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [Abstract] [Full Text] [Related]

  • 13. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
    Erduran F, Emre S, Hayran Y, Adışen E, Polat AK, Üstüner P, Öztürkcan S, Öztürk P, Ermertcan AT, Selçuk LB, Aksu EK, Akbaş A, Kalkan G, Demirseren D, Kartal SP, Topkarcı Z, Kılıç A, Yaldız M, Aytekin S, Hızlı P, Gharehdaghi S, Borlu M, Işık L, Botsalı BR, Solak EÖ, Albayrak H, Gönülal M, Balcı DD, Polat M, Daye M, Ataseven A, Yıldız S, Özer İ, Zorlu Ö, Doğan S, Erdemir VA, Dikicier BS.
    Arch Dermatol Res; 2024 May 25; 316(6):278. PubMed ID: 38796658
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO, Kıran R, Salman S, Cağlayan C, Aktürk AS, Bayramgurler D, Bilen N.
    J Drugs Dermatol; 2013 Sep 25; 12(9):1039-43. PubMed ID: 24002153
    [Abstract] [Full Text] [Related]

  • 15. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
    Carpentieri A, Pacello L, De Marco IM, Loiacono A, Picconi O, Loconsole F.
    J Dermatolog Treat; 2016 Oct 25; 27(5):399-405. PubMed ID: 26822691
    [Abstract] [Full Text] [Related]

  • 16. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
    Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM.
    N Engl J Med; 2011 Oct 27; 365(17):1586-96. PubMed ID: 22029980
    [Abstract] [Full Text] [Related]

  • 17. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study.
    Borghi A, Rizzo R, Corazza M, Bertoldi AM, Bortolotti D, Sturabotti G, Virgili A, Di Luca D.
    Dermatol Ther; 2014 Oct 27; 27(5):284-9. PubMed ID: 24909182
    [Abstract] [Full Text] [Related]

  • 18. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A, Tan E, Ilchyshyn A, Berth-Jones J.
    Br J Dermatol; 2006 Jun 27; 154(6):1169-74. PubMed ID: 16704650
    [Abstract] [Full Text] [Related]

  • 19. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
    Engin B, Tanakol A, Bulut H, Songür A, Vehid HE, Gökalp E, Kutlubay Z, Özkoca D, Tüzün Y, Serdaroğlu S.
    Int J Dermatol; 2020 Feb 27; 59(2):207-215. PubMed ID: 31531981
    [Abstract] [Full Text] [Related]

  • 20. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A.
    J Drugs Dermatol; 2015 Aug 27; 14(8):846-52. PubMed ID: 26267729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.